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As part of the biological rhythm, the human brain has a healthy functioning 
with the ability to differentiate between day and night hours in any given day 
(sleep rhythm, life rhythm). From the control of hormone levels to muscle tonus, 
from the regulation of respiratory rate to the content of our thoughts, sleep has an 
impact on all bodily and cognitive functions. It is not surprising to see such effects 
of sleep on the body as it leads to significant changes in the electrical activity of 
the brain in general. Electrical signal changes in the brain (sleep-wakefulness 
rhythm) are regulated by neurohormonal molecules and their receptors in the body. 
Neurotransmitters that control sleep and wakefulness can be listed as “Glutamate, 
Acetylcholine, Histamine, Norepinephrine and GABA”. Main hormones are: 
Melatonin, Corticotropin Releasing Hormone (CRH), cortisol, prolactin, Growth 
Hormone (GH), Insulin like Growth Factor (IGF-1, Somatomedin-C), Follicle 
Stimulating Hormone (FSH) and Luteinizing Hormone (LH), progesterone, 
estrogen, testosterone, catecholamines, leptin and neuropeptide Y″. The effects of 
pharmacological agents on sleep and wakefulness cycles are materialized through 
the following molecules and their receptors: Hypnotics (GABA A agonists, benzo-
diazepines, gabapentin, tiagabine), sedative antidepressants (tricyclic antidepres-
sants, trazadone, mitrazapine), antihistamines, medications used for the treatment 
of sleeplessness (melatonin and melatonin analogues), amphetamine (most com-
monly used stimulant), secretion of monoamines (dopamine), non-amphetamine 
stimulants used in the treatment of hypersomnia and narcolepsy (modafinil, 
bupropion, selegiline, caffeine) and other substances (alcohol, nicotine, anesthet-
ics). To the extent we can conceptualize the physiological mechanisms of these basic 
molecules listed above and the regions they affect, we can appreciate the effects of 
these substances on sleep physiology and sleep disorders.
Keywords: sleep-wakefulness rhythm, major neurohormones, neurophysiological 
effects of sleep-wakefulness molecules, basic sleep pharmacology
Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy
2
1. Introduction
A healthy interaction between wakefulness and sleep periods and a balance 
specific to the organism is necessary for the proper functioning of human physiol-
ogy and specifically that of the central nervous system (CNS) to be maintained. 
Sleep is a physiological need, it is a behavior during which the response of the brain 
to environmental stimuli is reversibly diminished. The absence or diminishment of 
this need negatively impacts the interactions in the neuronal networks and pathways 
responsible for the wakefulness of the brain. Electrical activity changes that appear 
in the brain during NREM and REM periods with the help of neurohumoral factors 
gives way to different physiological mechanisms in the body. Motor networks are 
integrated during REM, and non-motor ones during NREM. Thus, diseases that 
affect bodily organs and systems as well as medications can change NREM and REM 
activities thereby changing the motor and sensory functions of the brain. We can 
easily claim that many basic and clinical neurophysiological incidents taking place 
when we are awake are in fact realized through physiological processes and patho-
physiological mechanisms occurring during sleep. Anxiety disorders, depression 
and schizophrenia where neurotransmitter-receptor relationships are hindered, as 
well as motor and non-motor degenerative diseases (Amyotrophic Lateral Sclerosis, 
Parkinson’s disease) present with sleep disturbances and REM behavior changes 
years ahead of clinical symptoms. Sleep is as important a piece of life as wakefulness. 
As we continue to understand sleep, many of the causes of basic and clinical pro-
cesses from pediatric age to geriatric years will be further demystified.
2.  Neurophysiology of basic molecules affecting sleep and wakefulness 
mechanisms, fundamentals of sleep pharmacology
2.1  The relationship between behavior, limbic system and autonomous nervous 
system
When we talk about brain, we think about cortex; when cortex is mentioned, 
we focus on somatosensory (senses) and somatomotor (movement) cortex activi-
ties; when we hear about hypothalamus, we then consider hypothalamopituitary 
hormones and feedback mechanisms. Yet, humans are not limited to biological 
functions. Behavior is what defines a human being. Physiological and social charac-
teristics associated with behaviors and even habits can influence the diseases individ-
uals develop and the treatment approaches that are used. The emergence of behavior 
is managed by the limbic system which in itself means limit. Hypothalamus is at the 
center of the limbic system; rather than primarily focusing on biological-feedback 
interactions, it plays a key role in the integration and control of behavior [1–3]. The 
most important element of sleep and wakefulness cycle is our behavior model. Sleep 
is the most basic physiological need and the most important electrical activity of the 
brain influencing wakefulness behaviors (thirst, hunger, satiety, emotional state, 
mood, social motivation, love, compassion, argument, fear, attention, concentra-
tion, learning, memory and many other cognitive, motor, sensory and autonomous 
functions) [2–5]. Deep brain has hypothalamus at its center and it orchestrates affec-
tive sensations (like/dislike, satisfaction/revulsion, reward/punishment) together 
with surrounding limbic structures. As the main center of integration, hypothalamus 
uses parasympathetic and sympathetic fibers of the autonomous nervous system 
generating vegetative, emotional and motivational mechanisms. Amygdala is the 
main limbic structure for emotions: (1) it stimulates sympathetic activity, especially 
previously learned fear-related behavior. (2) Can be voluntary, when the cerebral 
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cortex decides to recall frightful experiences it acts through amygdala. (3) Some 
people can regulate some autonomic activities by gaining extraordinary control 
over their emotions. (4) It is sensitive to sleep deprivation that is why you get cranky 
when you have not slept enough. Reticular formation of brain stem, regulation of 
pupil size, respiration, heart, blood pressure, swallowing etc. Sleep/wakefulness 
cycle is a complex blend of all these physiological and behavioral processes. There 
are two distinct stages during sleep: a stage where there are no rapid eye movements 
NREM (Non Rapid Eye Movement) and one where there are rapid eye movements 
REM (Rapid Eye Movement). These stages are separated from one another and from 
wakefulness with hard limits [4–8].
2.2 Neuroanatomy of sleep and wakefulness behavior
There are two main regions (mesopontine reticular activating system (RAS) 
and hypothalamus; these two central regions modulate the intralaminar 
thalamus and neurons found in the basal forebrain) and a circadian pacemaker 
(Suprachiasmatic Nucleus (SCN)) with a central role that regulate the sleep and 
wakefulness cycle: RAS stimulates the cortex by ventral and dorsal tracts. Ventral 
tract stimulates the frontal parts of the brain through hypothalamus and subthala-
mus, dorsal tract stimulates it through the nucleus groups in the thalamus. During 
wakefulness, transmission of sensory information from thalamus is permitted 
through RAS control managed by thalamus. During sleep, the activity of RAS stops 
and the transmission of sensory information through thalamus is blocked and the 
stimulation of cortex is prevented. Anatomic structures responsible for the hypo-
thalamic control of sleep and wakefulness: for wakefulness, stimuli originating 
from rostral pons and caudal midbrain regions reach paramedian midbrain in 
diencephalon and here, the signals divide into two paths aiming to reach thalamus 
and hypothalamus. Main structures projecting to thalamus are PedinculoPontine 
Tegmental (PPT) and LateroDorsal Tegmental (LDT) nuclei that are of cholinergic 
nature. The structure that initiates sleep is thought to be the ventrolateral preoptic 
nucleus (VLPO) located on the anterior part of the hypothalamus. VLPO suppresses 
the activities of brain stem, pons and locus coeruleus (LC), dorsal raphe nucleus 
(RN), laterodorsal tegmental pedinculopontine tegmental nucleus via GABA and 
galanine neurotransmitters. Suprachiasmatic Nucleus (SCN) is known as the light 
sensitive circadian pacemaker. During daytime, light stimulus is transmitted from 
retina to hypothalamus through neural pathways and it results in the secretion of 
melatonin from the pineal gland. It is an anatomical structure that has a central role 
in maintaining the day-night rhythm [1, 9–11]. It is multisynaptic and sympathetic 
nervous system contributes to this.
2.3 Physiology of neurotransmitters for sleep and wakefulness
2.3.1 Basic neurotransmitters for sleep and wakefulness cycle and a neurohormone
Dopamine: It is synthesized from L-Dopa with aromatic L-amino acid decar-
boxylase enzyme (cofactor pyridoxine). Dopamine receptors: D1 receptor; is found 
on nigrostriatal pathway specifically on nucleus caudatus, it plays a role on the 
initiation of locomotor system movements. D2 receptor; is found prominently in 
striatum and mesolimbic pathways, it plays a role in motor effects associated with 
extrapyramidal system. D3 receptor; is mostly found in the limbic system, it plays 
an important role in emotional and cognitive processes. D4 receptor; is increased 
in number in schizophrenia. D5 receptor; is important for the dopamine/acetyl-
choline balance in the basal ganglia and in maintaining a normal somatomotor and 
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striated muscle tone. Parkinson and Huntington chorea are prototypic diseases for 
decreased and increased dopaminergic activity, respectively. Dopamine decreases 
the secretions of prolactin and TRH [12–14].
Serotonin (5-hydroxytriptamine, 5-HT): L-Tryptophan is converted into 
5-hydroxytryptamine (5-HT) with tryptophan hydroxylase (5-hydroxytrypto-
phane) and amino acid decarboxylase enzymes. Most of the serotonergic pathways 
are found within the Raphe system (2 pathways) in the brain. (1) Ascending 
pathway: Regulation of feeding behavior (decreases the appetite together with 
histamine and nicotine), continuation of normal behavioral patterns, regulation of-
NREM-REM sleep cycle, hormonal regulation (increases ACTH and prolactin secre-
tions, decreases GnRH secretion), depression, anxiety and migraine pathogenesis. 
(2) Descending pathway: Acts as a modulator in the transmission of pain sensation 
to the central level. Serotonin receptors: 5HT1-A: Shows an anxiolytic effect. 5HT1-
B: It is a presynaptic inhibitor. 5HT1-D: Closes the AV shunts in the brain, plays a 
role in migraine pathogenesis. 5HT2: Has excitatory effects on behavior. 5HT2-C: 
Specifically found in choroid plexus where atypical antipsychotic clozapine exerts 
its effects. 5HT3: Stimulates the respiratory center and is found in the autonomous 
nervous system. 5HT4: Primarily found in the myenteric plexus within the gastroin-
testinal system [12–14].
Adenosine: It is a nucleoside naturally found in all bodily cells. It forms mol-
ecules like adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to 
transmit energy inside the cells; at the same time, it is one of the chemical messen-
gers (xanthine) or neurotransmitters in the brain. It is a substance that is produced 
either directly or as a result of ATP hydrolysis. It is broken down by adenosine 
deaminase. It has 2 known receptors: P1 (A1–4) and (A1 and A2 receptors are 
blocked by methyl xanthines) P2X-2Y. It has depressant effects on the CNS. As an 
inhibitor transmitter in the brain, it shows an incremental increase specifically in 
RAS throughout the wakefulness period; when it reaches its highest level, adenosine 
inhibition takes place, sleep starts and adenosine concentration gradually decreases 
during sleep. Caffeine blocks the depressant effects of adenosine on the brain, 
decreases adenosine inhibition and provides for the continuation of wakefulness 
while carbamazepine (adenosine agonist, antiepileptic) helps to continue adenosine 
inhibition [15–17].
Melatonin (A neurohormone that identifies daytime and nighttime): It plays 
an important role in identifying the circadian rhythm. It is synthesized from 5-HT 
in the pineal gland by acetyltransferase and methyltransferase enzymes. Melatonin 
receptors are mostly found in SCN. The physiological actions of melatonin are 
mediated by two G-protein coupled membrane receptors, which belong to the 
family of the quinone reductases. Melatonin receptors: MT1; is primarily found 
in the human skin. It is associated with the aging process and Alzheimer’s disease. 
MT1 and MT2 receptors are expressed in the SCN and they have distinct functional 
roles in sleep regulation. Activation of the MT1 receptor suppresses neuronal firing 
rates in the SCN, while MT2 mainly acts by inducing circadian rhythm phase shifts. 
MT2; has anxiolytic, antidepressant and hypnotic effects and is related to pain 
pathophysiology. MT3; is related to quinone reductase enzyme and it plays a role in 
the prevention of stress as well as detoxification [18–20].
2.3.2 Neurotransmitters in charge of sleep and wakefulness
“Glutamate, Acetylcholine, Histamine, Norepinephrine and GABA”.
Glutamate: It is the main excitatory neurotransmitter in the brain and medulla 
spinalis. Its inactive form is glutamine. It plays a primary role in the generation of 
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excitatory postsynaptic potentials and long-term potentiation in the brain and these 
are the most important mechanisms in learning and memory formation. Its most 
important receptors are: NMDA (N-methyl-D-aspartate; it is a Na+-K+-Ca++ channel 
type receptor, its selective antagonist is phencyclidine and its endogenous blocker 
is Mg++), AMPA (alpha-amino-3-hydroxy-5 methyl-4- isoxazole propionic acid), 
Kainate (kainic asid) receptors (KARs) [12–13].
Acetylcholine: It has muscarinic and nicotinic receptors in the CNS. Nearly 80% 
of the cholinergic pathways in the brain originate from Meynert’s nucleus basalis. 
Nicotinic receptors are mainly found in Renshaw cells that inhibit alpha motor neu-
rons in medulla spinalis. In addition to learning and memory functions, they also 
play a role in the balanced functioning of the extrapyramidal system. A parallelism 
has been shown between the degeneration of this pathway and the occurrence of 
Alzheimer’s disease and Huntington chorea [12–14].
Histamine: Ventral posterior hypothalamus and tuberomamillary nucleus 
(TMN) receiving histaminergic projections have the highest concentrations of 
histaminergic neurons in the brain. H1 receptors are found in glial cells and H3 
receptors are in basal ganglia. Serotonin-like effects of histamine are: (1) to decrease 
the appetite and (2) to increase the secretion of ACTH and prolactin [13, 14].
Norepinephrine: In the CNS, catecholaminergic neurons are most abundant 
in locus coeruleus. The highest concentrations of norepinephrine are found in 
hypothalamus, nucleus amygdala and the dentate gyrus of hippocampus. Medullar 
reticular formation harbors the highest levels of epinephrine. It has Beta 1 and 
2 activator receptors which are widespread in the CNS. Alpha 1 causes vigilance 
(behavioral activations). Alpha 2 acts as an autoreceptor at presynaptic level and 
is inhibitory in nature (sedation). The activation of this system in the CNS leads to 
panic reaction presenting with alertness, fear and a state of alarm. Furthermore, 
it causes anxiety and tremor. However, the decrease in the efficacy of this system 
leads to depression. Catecholamines also increase the secretions of GnRH and 
ACTH [12–14].
Gamma-Aminobutyric Acid (GABA): It is the main inhibitory mediator of 
the brain. GABA is synthesized from glutamic acid by glutamic acid decarbox-
ylase enzyme (activated by valproic acid). The main route of its inactivation in 
the synaptic space is re-uptake and it is broken into succinic acid semialdehyde 
by the GABA transaminase enzyme (inhibited by vigabatrin). It has two recep-
tors of inhibitory character: (1) GABA-A receptor is a chlorine channel. When 
it is activated, due to the influx of the Cl ions, intracellular negativity increases 
(hyperpolarization). This receptor has 5 subunits (2 alpha, 2 beta, 1 gamma): The 
agonist for the beta subunit is muscimol, its antagonist is bicuculline; alpha subunit 
is a benzodiazepine receptor. Barbiturate is a Cl channel agonist, while picrotoxin 
and pentylenetetrazole are antagonists. It has binding regions for ethanol and 
ivermectin. (2) GABA-B receptor is not of ion channel character. It is not affected 
by benzodiazepines or barbiturates. It is activated by baclofen and antagonized by 
faclofen and saclofen [14–16].
2.3.3 Mechanism of action of neurotransmitters on sleep and wakefulness neurons
Reticular activating system stimulates the cortex by utilizing glutamate while 
ponto-mesencephalic tegmental neurons do this by using acetylcholine. Neurons at 
locus coeruleus predominantly utilize norepinephrine, they extend from the brain 
stem to the cerebral cortex encompassing the forebrain; by activating the stimula-
tion of the cortex, and they contribute to maintaining wakefulness. Cholinergic 
neuronal network leads to wakefulness in two types of cortexes:
Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy
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1. It projects to laterodorsal tegmental and pedinculopontine tegmental nuclei, 
midline and intralaminar thalamic nuclei and to a lesser degree to lateral  
hypothalamus and basal forebrain.
2. Cholinergic neuron group starts from the basal forebrain with a widespread 
projection to cortex. This pontomesencephalic neuron group is a part of the 
ascending reticular activating system; they play a part in the activation dur-
ing wakefulness and are actively involved in paradoxical sleep. Glutamate is 
another excitatory neurotransmitter acting as the primary neurotransmitter 
of the ascending reticular activating system. Glutamate is found at very high 
concentrations at the brainstem reticular formation. It plays an active role in 
the wakeful brain and is secreted from the cortical cells during wakefulness. 
During deep sleep, slow wave sleep (SWS) “burst discharges” appear as a result 
of the activation of special glutamate receptors. Histamine plays an impor-
tant role in wakefulness as well. Histamine containing neurons are found in 
tuberomammillary nuclei and posterior hypothalamus. Noradrenergic neu-
rons (locus coeruleus), have diffuse projections in the brain extending to the 
cortex. Histaminergic neurons are associated with cortical activation during 
wakefulness while they are shut down during REM sleep. Sleep requires a shift 
from sympathetic regulation to parasympathetic regulation. Parasympathetic 
centers of significance are located in “solitary tract nucleus neurons, anterior 
hypothalamus and preoptic fields”. When increasing adenosine concentrations 
in RAS reach their highest levels, serotonergic raphe neurons facilitate the 
beginning of sleep while GABA-ergic neurons inhibit the activating system. 
These GABA-ergic neurons are selectively activated during SWS. As a result of 
this inhibition, brain stem, hypothalamus and nasal forebrain are suppressed 
and disfacilitation (inhibition) and hyperpolarization of thalamocortical 
system takes place. Thereby, from the wakeful state where we see rapid, tonic 
discharges on EEG, the system shifts into sleep state where we start recording 
sleep spindles and slow wave activity. Initiation and continuation of SWS is 
made possible by lengthening and strengthening the inhibition of the activat-
ing system with GABA-ergic system. Metabolic rate of adenosine dictates sen-
sitivity to sleep deprivation while directly influencing the quality and duration 
of SWS [6, 9, 20–25].
2.3.4  The physiology of the circadian system and melatonin in the regulation of 
circadian rhythm
In Latin, circa means pertaining to and dian means day; circadian is a word used 
to explain the daily physiological rhythms of an organism, mainly the sleep and 
wakefulness.
The anatomy of the circadian rhythm: The regions in charge of the circadian 
rhythm in mammals are the right and the left suprachiasmatic nuclei (SCN) 
located in the anterior hypothalamus. SCN is divided into ventrolateral and 
dorsomedial sections on the basis of biochemical structure, peptide phenotypes 
and afferent-efferent pathways. SCN is affected by environmental changes such 
as light and time of nutrition. SCN also has functional regions that regulate 
circadian rhythm outputs associated with neural activity. Light is perceived by 
retinal photoreceptors (cones, rods, retinal ganglion cells containing melanopsin). 
The action potentials that are generated here lead to the secretion of glutamate 
and pituitary adenylate cyclase activating polypeptide via retinohypothalamic 
pathways. Information about light intensity and temporal stimulus is directly 
transmitted to SNC while it is indirectly transferred to the lateral geniculate region 
7
Neurophysiology of Basic Molecules Affecting Sleep and Wakefulness Mechanisms, Fundamentals…
DOI: http://dx.doi.org/10.5772/intechopen.100166
in the thalamus. SCN receives significant inputs from serotonergic median raphe 
nucleus and intergeniculate region containing neuropeptide Y and GABA (These 
regions are not essential for circadian rhythm; however, they transfer information 
about light sensitive phase changes and stimulants other than light to the circadian 
rhythm center). The effects of light on SCN activity and circadian phase changes 
are completely opposite of those of neuropeptide Y and serotonin. As the center of 
circadian rhythm, SCN contributes to the regulation of behavioral, physiological 
and genetic rhythms. The most important aspect is its relationship with hypo-
thalamus; (1) Main neuronal pathway regulating sleep-wakefulness rhythm SCN 
– neighboring supraventricular region, SCN-dorsomedial hypothalamic region (2) 
SCN-sends both direct and indirect fibers to paraventricular hypothalamic nucleus 
regulating corticosteroid secretion and melatonin synthesis. The regulation of 
the circadian rhythm improves the adaptation of the organism to life; towards the 
end of a night’s sleep, body temperature, plasma cortisol levels and sympathetic 
autonomous activity all increase. When sleep time approaches, body temperature 
decreases and melatonin secretion starts. In mammals, circadian rhythm center at 
SCN regulates the phases and timings of all cyclical behavioral functions together 
with sleep-wakefulness cycle. Identifying the neuronal pathways and neurotrans-
mitters playing a role in this regulation is crucial for developing pharmacological 
and strategical approaches for chronobiological sleep disorders [25–27]. Melatonin 
in the regulation of sleep and circadian rhythm: Melatonin is the neuroen-
docrine modulator of day-night rhythm with receptors densely located at the 
suprachiasmatic nucleus (SCN). The endogenous circadian rhythm of melatonin 
secretion is directly proportional to the endogenous rhythm of sleep tendency. 
Secretion of melatonin from the pineal gland is controlled by SCN. This pathway 
is multisynaptic and has contributions from the sympathetic nervous system. 
When administered to the body from outside melatonin helps initiate sleep; as 
it leads to phase shifts, it has therapeutic effects in insomnia and regulation of 
sleep-wakefulness phases. The biological clock can be regarded as an insurance 
preventing sleep phase shifts caused by homeostatic changes. When human beings 
intend to change the timing of sleep-wakefulness rhythms at their own will (most 
common causes are travels to regions with time differences and working with 
shifts), insomnia ensues. Sleep regulation, Homeostasis, Sleep homeostasis and 
Sleep-wakefulness rhythm: Three main processes play a role in sleep regulation: 
(1) Homeostatic process which tells us the relationship between the last sleep and 
wakefulness periods. In sleep deprived organisms the duration and depth of sleep 
increases as a compensatory mechanism. (2) Circadian process; in other words the 
biological clock. (3) Ultradian process which defines the duration of REM—NREM 
sleep cycles and the interactions between them. Sleep wakefulness rhythm is 
identified by circadian and homeostatic processes. Homeostasis is the preservation 
of required internal environment conditions (extracellular fluid) for maintain-
ing the vitality of the organism. Sleep homeostasis is the equivalent of sleep-
wakefulness balance in sleep regulation. This balance is maintained by homeostatic 
mechanisms and deviations from the normal are either normalized or brought 
closer to normal. Circadian process can be regarded as an internal clock that lasts 
24 hours. Homeostatic process is related to the time spent awake before sleeping. 
Therefore, there are three important features of a medication to be used in the 
treatment of insomnia caused by circadian clock changes: (1) Hypnotic effect: 
the ability to initiate or to maintain sleep when homeostatic effect is inadequate 
to do so. (2) Chronohypnotic effect: the ability to inhibit the time of waking-up 
normally regulated by the circadian center. (3) Chronobiotic effect: concerning the 
regulation of the circadian rhythm, the ability to initiate phase shifts and to do so 
during desired hours. Melatonin is a hormone that harbors all these three features. 
Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy
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Secretion of melatonin from the pineal gland is controlled by SCN. Furthermore, 
it is multisynaptic and has contributions from the CNS. If there is light exposure 
during night hours, melatonin levels decrease immediately. Melatonin levels are 
influenced by certain medications: Beta blockers used for the prophylaxis of 
hypertension, cardiac arrhythmias and headaches block the sympathetic activ-
ity both at the heart and at the pineal gland. On the other hand, antidepressant 
drug fluvoxamine prevents the degradation of melatonin and increases its plasma 
concentrations. Administration of 0.3–80 mg oral melatonin during daytime when 
endogenous melatonin levels are low, will decrease sleep latency and have a sleep 
inducing effect. Melatonin effect is related to body posture; it increases when lying 
down and decreases when standing up. Neurotransmitter imbalance is present in 
SCN of essential hypertension patients and there is a decrease in the secretion of 
melatonin in coronary artery disease that follows. In patients with uncontrolled 
hypertension, taking 2.5 mg of melatonin 1 hour before sleep is shown to increase 
the total duration and the efficacy of sleep. EEG pattern of sleep regulation: 
Sleep regulation is mainly identified by sleep homeostasis: in sleep deprivation, 
the length of sleep increases and it gets deeper as a compensatory mechanism. 
Because sleep needs are identified by the homeostatic and circadian processes. As 
the time spent awake before sleeping increases, slow waves in sleep EEG increase 
and sleep spindles decrease. Neurophysiologically, thalamocortical neurons have a 
moderate level hyperpolarization during the superficial stages of NREM sleep (N1 
and N2) and high level of polarization during deep stages (N3) of NREM. During 
superficial NREM sleep, there are more frequent thalamocortical discharges and 
EEG equivalent of these are sleep spindles. Theta activity in awake EEG shows the 
homeostatic process. As the period spent awake gets longer, theta activity increases 
and SWS (delta) activity increases to the same extent. Despite the fact that their 
mechanisms of action are different, similar to benzodiazepines the use of melato-
nin suppresses low frequency EEG activity [27–29].
2.4 The effects of sleep and circadian rhythm on hormones
Circadian rhythmicity and sleep-wakefulness homeostasis includes; (1) the 
modulation of hypothalamic hormones, peptides and molecules, (2) the metabolic 
pathways influenced by peripheral hormones and (3) autonomous nervous system 
control of endocrine organs. In the regulation of temporal organization of hormone 
secretion, processes associated with the electrical signal changes during the sleep 
stages of brain (NREM-REM) are as effective as circadian rhythm and homeo-
static processes. These processes effect different hormonal axes (somatotropic, 
corticotropic and gonadal axes) and metabolic pathways at different levels. For 
example thyroid stimulating hormone (TSH) levels might change both with sleep 
and circadian rhythm while cortisol levels only change with circadian rhythm. 
Growth hormone (GH) and prolactin (PRL) can be at a certain level during day-
time- wakefulness but they increase while sleeping. Glucose and insulin have been 
shown to be effected by both sleep and the circadian rhythm increasing while being 
awake at night and while being asleep during daytime. Circadian oscillations can 
be generated in many peripheral organs under autonomous nervous system control 
including adipocytes and pancreas beta cells that generate endocrine signals. These 
“local” oscillators seem to be under the control of central electrical batteries found 
in suprachiasmatic nuclei either directly through neural and endocrine signals 
or indirectly via sleep-wakefulness cycle and behavioral rhythms like nutrition. 
Endocrine secretion of these peripheral oscillators during wakefulness and sleep 
and their possible participation in the temporal organization of metabolic function 
are still open to research [30–32].
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2.4.1 Somatotropic axis and sleep
Growth Hormone (GH): Pituitary secretion of GH is stimulated by hypotha-
lamic GH secreting hormone (GHRH) and is inhibited by somatostatin. Acylated 
form of ghrelin that is predominantly produced in the stomach binds to growth 
hormone secreting (GHS) receptors and endogenously stimulates GH secretion. 
GH is a respiratory stimulant. Animal studies have shown that the infusions of 
GHRH and ghrelin result in SWS, while GH infusion leads to REM sleep. There is a 
consistent relationship between the presence of Delta waves on EEG and high con-
centrations of GH and maximum GH secretion takes place minutes after the start 
of SWS. Pharmacological agents used in narcolepsy like gamma hydroxyl butyrate 
(GHB) and ritanserin that stimulate SWS cause an increase in GH. Sleep-initiated 
GH secretion is regulated by GHRH stimulation that primarily takes place during 
somatotropin inhibition where somatotropic activity decreases. Secretion of GH 
during early sleep is suppressed by the administration of a GHRH antagonist [15]. 
SWS decreases with age and there are also medical conditions that result in sleep 
fragmentation which all decrease GH secretion. Sleep deprivation effects GH secre-
tion through deteriorations in both the circadian rhythm and sleep-wakefulness 
homeostasis. Insulin like Growth Factor (IGF-1) (Somatomedin C): It is a hor-
mone primarily synthesized in the liver by being stimulated with GH. It mediates 
the anabolizing effects of GH in the muscle tissue. In men it decreased after 21 years 
of age while there is a rapid decline in women after menopause. It is a respiratory 
stimulant like GH and leads to increases in SWS. Somatostatin: Inhibits the GHRH 
stimulation of GH secretion. It has a suppressive effect on the respiratory center and 
is thought to play a role in sudden infant death syndrome [33–35].
2.4.2 Corticotropic axis and sleep
The activity of the corticotropic axis is related to stress reaction and behavioral 
activation. Corticotropic axis activity can be measured peripherally by plasma levels 
of pituitary adrenocorticotropic hormone (ACTH) and adrenal hormone cortisol 
that is directly controlled by ACTH stimulation. Plasma levels of these hormones 
are highest during early hours of morning, they decrease throughout the day reach-
ing lowest limit during late night hours and early stages of sleep period. Therefore, 
sleep is normally initiates when corticotropic activity is slow. Reactivation of ACTH 
and cortisol secretion happens suddenly a couple of hours ahead of waking up. 
Corticotropin releasing hormone (CRH): It regulates GnRH secretion and stimu-
lates adrenocorticotropic hormone secretion (ACTH) from the pituitary gland. It 
binds to CRH receptors that are abundant in the brain and stimulates breathing. 
In instances of stress it acts as a part of hypothalamo pituitary adrenal axis and 
increases plasma cortisol levels. Cortisol: Physiologically low levels of cortisol at 
the beginning of sleep is correlated with SWS and cortisol secretion mostly starts 
during superficial stages of sleep. When there is sleep deprivation, cortisol levels 
act in parallel to circadian rhythm increasing and decreasing at the same time; 
however, as there is a change in the time sleep starts and ends, cortisol levels are 
somewhat higher during nighttime (where it should be lower), and somewhat 
lower during the day (where it should be higher) (thus the amplitude of cortisol 
rhythm decreases). In elderly individuals with fragmented sleep and decreased 
SWS, worsened memory and insulin resistance that is observed is related to the 
increased cortisol levels at night. Waking up during fragmented sleep results in 
increases in cortisone levels (as concerns cortisol increase and sleep fragmentation, 
it is not clear which one is the cause and which is the result). Cushing patients were 
shown to have bad sleep quality, decreases in REM latency, increases in first REM 
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intensity and decreases in deep sleep. Addison patients also had decreases in deep 
sleep. Therefore, we can conclude that for deep sleep to happen, the organism needs 
cortisol rhythm within normal limits [36–38].
2.4.3 Thyrotropic axis and sleep
Thyroid Stimulating Hormone (TSH)-Triiodothyronine (T3)-Thyroxine 
(T4): It is stable throughout the day and increases during the early hours of the 
evening reaching its maximum level at the beginning of sleep. Before waking up 
in the morning, it returns to its stable levels that continue through the day. TSH 
secretion is influenced by the circadian rhythm and by sleep. Sleep had an inhibi-
tory effect on TSH. This effect disappears during sleep deprivation, nocturnal 
TSH levels increase together with increases in T3 and T4. Thyroid hormones are 
respiratory stimulants. In hypothyroidism, there is a tendency for hypoventilation 
and obstructive apnea syndrome. There is sleepiness during daytime and decreases 
in SWS. In hyperthyroidism, there is increased movement during sleep, decreased 
REM duration and insomnia due to increased metabolic rate [39, 40].
2.4.4 Prolactin (PRL) and sleep
PRL levels begin to increase shortly after the start of sleep and make a night 
peak at the middle of sleep. The possible primary mechanism underlying this peak 
is decreased dopaminergic inhibition of PRL during sleep. Thyrotropin releasing 
hormone (TRH), vasoactive intestinal peptide (VIP), oxytocin, estrogen and angio-
tensin II increase PRL secretion while dopamine, GABA and acute hypoxia inhibits 
it. The primary effect of PRL during sleep is to stimulate REM sleep. Rapid PRL 
increase at the beginning of sleep is thought to be related to SWS. In prolactinoma 
and lactating mothers SWS increases due to increased PRL secretion. Fragmented 
sleep decreases PRL secretion (Mechanism: Waking up in the morning and wakeful-
ness that fragment sleep are related to a rapid inhibition of PRL secretion) [41, 42].
2.4.5 Gonadal axis and sleep
The relationship between 24-hour-gonadotropin secretion rhythms and gonadal 
steroid levels changes based on the stage of maturity and is sex-related during 
young adulthood [42].
Gonadotropins: Before puberty, luteinizing hormone (LH) and follicle stimu-
lating hormone (FSH), is secreted in a pulsatile fashion both in boys and girls. 
Increased amplitude of gonadotropin secretion during sleep is a distinctive char-
acteristic of adolescence. In adolescent girls, estradiol levels are higher during the 
day than the night; in adolescent boys high levels of testosterone during nighttime 
coincide with increases in gonadotropins. Both sleep and circadian rhythm con-
tribute to the increases in gonadotropin pulsations during the night in adolescents. 
As they transition into adulthood, the effect of circadian rhythm either decreases 
or disappears completely. In sleep deprivation, LH increases, FSH does not change. 
Adult 24-hour plasma LH levels are regulated by the menstrual cycle in women, 
in men it changes according to NREM-REM cycles. In young men, REM sleep 
deprivation weakens night increases of testosterone in particular. In elderly men, 
there is a decrease in LH secretion during sleep while it increases in elderly women; 
however this is not in relation with the circadian rhythm. Progesterone: It increases 
during pregnancy and during the luteal phase of menstrual cycle. As it is a respira-
tory stimulant, there are low carbon dioxide levels and hyperventilation during 
these periods. When progesterone decreases during the postmenopausal period, 
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nocturnal desaturation, hypopnea and apneas are seen more frequently. In individ-
uals administered with estrogen and progesterone during postmenopausal period, 
sleep breathing disorders were less common. Estrogen: In young women, it is at 
its lowest level during menstruation and at its highest during the midluteal phase 
(estradiol). It is in the form of estrone during postmenopause. Estradiol increases 
the effects of progesterone on respiration by increasing the number of progesterone 
receptors. Testosterone: Despite the low amplitude of nighttime increase in gonad-
otropin secretion, there is a significant diurnal rhythm for testosterone levels in the 
circulation. Testosterone is at its lowest levels during the late hours of the night; 
after sleep starts, there is a strong increase and it reaches its maximum levels during 
the early hours of the morning [51, 52]. Therefore, the strong circadian rhythm of 
plasma testosterone can be partially controlled by factors other than LH. Nighttime 
increase of testosterone is temporarily related to the delay of first REM episode. 
There are studies showing that sleep breathing problems are due to decreased levels 
of testosterone during nighttime as well as those showing that respiratory stimula-
tion is decreased by the negative effect on progesterone [43–46].
2.4.6 Catecholaminergic axis and sleep
With initiation of sleep, noradrenaline and adrenaline levels decrease as the case 
with cortisol reaching their minimum levels within an hour. Noradrenaline plays a 
role in respiratory control while adrenaline is a bronchodilator. Nocturnal catechol-
amine levels are increased in patients with obstructive apnea syndrome.
2.5  Physiological mechanisms of basic molecules that cause sleep related 
metabolic changes
2.5.1 Molecules mediating nutrition and sleep regulation
Sleep plays an important role in energy balance. Hypocretins and orexins are 
hypothalamic stimulant neuropeptides with strong wakefulness promoting effects, 
they also stimulate feeding; their definition created the molecular basis for delineat-
ing the interactions between nutrition and sleep regulation.
Orexin: Orexin containing neurons in lateral hypothalamus directly lead to 
locus coeruleus and other brainstem and hypothalamic stimulation areas; here 
they interact with leptin sensitive neuronal network which plays a role in balanc-
ing food intake and energy consumption. Orexin containing neurons are active 
when awake and inactive when asleep. Orexin activity is inhibited by leptin which 
is a satiety hormone and stimulated by ghrelin, an appetite stimulating hormone. 
Leptin: Leptin is a hormone secreted by adipocytes, it provides information to 
the regulating centers at hypothalamus about energy status. Nighttime increases 
of leptin is thought to suppress hunger during night fasting. When administered 
systemically, it causes increases in SWS and decreases in REM. As it inhibits 
Neuropeptide Y (suppresses respiration) secretion, it stimulates corticotropin 
releasing hormone-CRH (stimulates respiration) secretion. Research trials have 
shown that it stimulated respiration and that CPAP (continuous positive air pres-
sure) treatment decreased leptin receptor sensitivity. Long term total sleep depriva-
tion decreases leptin levels. Ghrelin: It plays a role in regulating energy balance and 
stimulating appetite. Ghrelin levels increase sharply before each fixed meal time 
and make a nadir 1–2 hours after eating. Although hunger continues, ghrelin levels 
do not continue to increase throughout sleep and decreases during later hours of 
sleep instead. When at high levels during sleep, it is a strong endogenous stimulant 
of GH secretion [43, 47–49]. Neuropeptide Y (NPY): NPY is widely distributed 
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in hypothalamus, amygdala, locus coeruleus and cerebral cortex. At least six NPY 
receptor subtypes have been defined. NPY plays a role in food intake, hormonal 
secretion, circadian rhythms, stress reaction, anxiety and sleep functions. In 
animals, depending on the site of injection, NPY was found to have sleep promoting 
effects as well as wakefulness effects. In humans, NPY is thought to have hypnotic 
characteristics and act as a physiological antagonist of CRH. NPY participates in the 
timing of sleep onset in humans and can thus play a role in the integration of sleep 
regulation, food intake and metabolism [43, 50].
2.5.2 Autonomic nervous system co-transmitters (neuropeptides)
Nuclei located in hypothalamus (posterior and lateral regions contain sympa-
thetic nuclei, anterior regions have parasympathetic ones) control the autonomic 
nervous system. Together with hypothalamus and limbic structures, sympathetic 
and parasympathetic portions of the autonomic nervous system regulate vegeta-
tive sensory and motivational behaviors. Norepinephrine (noradrenaline) is the 
main transmitter for the sympathetic system (catecholaminergic system), and 
Neuropeptide Y acts as a cotransmitter. In vascular beds, adrenergic endings secrete 
NPY together with noradrenaline. By itself, NPY has a vasoconstrictor effect. 
Acetylcholine (Ach) is the main transmitter of the parasympathetic system (cholin-
ergic system) and VIP (vasoactive intestinal peptide) functions as the cotransmitter 
of this system. In the salivary and perspiratory glands, in the genital system and 
adrenal medulla cholinergic endings secrete VIP together with ACh. VIP exerts 
partial vasodilator and strong bronchodilator effects [7, 12–14].
2.5.3 Melanin-concentrating hormone (MCH)
MCH, is a 19 amino acid long cyclic neuropeptide acting as a neurotransmit-
ter. Neurons containing MCH are primarily found in lateral hypothalamus and 
incerto-hypothalamic regions and they have widespread projections within the 
brain. In humans, biological functions of this neuropeptide are realized via two 
metabotropic receptors, namely MCHR1 and MCHR2, whereas rodents only have 
MCHR1. General functions in the organism: (1) Feeding behavior and energy 
conservation; high concentrations of MCH, might lead to increased eating and is 
associated with increases in body mass. On the contrary, decreases in existing levels 
of MCH can lead to decreased eating. Increased MCH levels in olfactory regions 
have been associated with the consumption of oily foods with high calorie content. 
Good tasting food items promote MCH encouraging higher consumption of them. 
Sugar, specifically glucose seems to be supporting the role of MCH in sleep and 
energy conservation. Supporting energy conservation in this manner has been asso-
ciated with high body mass even when the diet is under control. (2) Having MCH 
at certain locations only during lactation seems to help promote maternal behavior. 
(3) Reproduction: MCH has been assumed to act as a modulator in Luteinizing 
Hormone (LH) secretion by having a direct effect on the pituitary gland or by indi-
rectly influencing gonadotropin releasing hormone (GNRH) in the hypothalamus. 
Estrogen seems to be required for MCH to influence reproduction. (4) Skin pig-
mentation: MCHR1 has been found in human melanocytes and certain melanoma 
cells. In these cells, it has an antagonistic relationship with α-MSH and it decreases 
melanin production. Specific regulation of sleep behavior: As concerns the sleep 
cycle, MCH and orexin have an antagonistic relationship with one another, orexin is 
nearly totally active during wakefulness periods and MCH is more active. MCHergic 
neurons are more active during sleep, specifically during REM sleep; although 
they increase SWS as well, they mainly increase the duration of REM sleep. MCH 
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knockout mice have shorter REM sleep especially under negative energy balance 
circumstances. Systemically administered MCHR1 antagonists decrease sleep. 
While MCH promotes sleep, there are limited number of studies associating 
MCH with narcolepsy. Narcolepsy has long been described as a disorder of REM 
sleep mechanism. An individual with narcolepsy starts sleeping with REM sleep. 
Narcolepsy presents with the loss of hypothalamic cells that contain hypocretin and 
orexin. A research study has demonstrated that individuals having narcolepsy had 
diminished orexin neurons that would promote wakefulness and that the number 
of MCH neurons was not different than those of an average individual who does not 
have narcolepsy. MCH has been associated with depression and anxiety. MCHR1 
antagonists were shown to act as antidepressants. [1] Chemokines and cytokines 
generally appear as a result of inflammation or infection and can then damage MCH 
neurons thereby possibly causing anorexia in an individual. MCH has been identi-
fied both in melanoma and squamous cell carcinoma cell lines [43, 51–54].
2.6 Overview (a general look at sleep related neuropharmacology)
The system and molecules that are in charge of regulating sleep-wakefulness 
modulate general homeostatic mechanisms as well as orchestrating highly cogni-
tive activities like attention, learning and memory. We need to develop a general 
perspective for pharmacologic substances influencing these activities.
2.6.1 Alcohol
Ethyl alcohol; blocks glutamate NMDA receptors and is an indirect agonist 
of GABA receptors. Cerebral granular cells increase GABAergic transmission in 
cerebellar cortex and hippocampus. Alcohol is neurotoxic at high doses; it can 
specifically hinder cholinergic input that advances to the cortex through basal 
forebrain neurons. It can lead to a significant deterioration in motor performance 
and can result in sleep deprivation. There might be behavioral problems stemming 
from sleep deficiency as well as memory problems in alcoholics because of apparent 
effects of alcohol on hippocampus. Individuals having undiagnosed schizophrenia, 
anxiety disorders and depression might try to benefit from sedative and anxiolytic 
effects of alcohol by overconsumption. In these individuals, blood circulation to the 
frontal region deteriorates and their decision making capacity is impaired [14, 15].
2.6.2 Anesthetics, sedatives and hypnotics
Main mechanisms of effect for sleep inducing pharmacological agents are still 
being delineated. The primary site of action of most anesthetics may be the sleep– 
wake control system. In anesthesia, considering that arousal and alertness represent 
a continuum of levels from mania to coma, with physiological and behavioral 
concomitants, the monitoring of EEG, along with behavioral and autonomic signs, 
should be used routinely to assess level of anesthesia. Most anesthetics, including 
barbiturates, etomide, propofol, neuroactive steroids, and volatile anesthetics, 
act on GABAa receptors among other receptors. Sedation and natural sleep occur 
greatly as a result of enhanced GABAergic transmission, which in turn affects the 
release of a number of excitatory transmitters such as acetylcholine, excitatory 
amino acids, and histamine. Actions may take place specifically in such regions 
as the RAS, TMN, and basal forebrain (all of which have local circuit GABAergic 
neurons and receive GABAergic input from VLPO, as described earlier), thereby 
regulating the level of arousal. The benzodiazepines act by binding to a site that 
modulates GABA receptors, especially GABAa receptors. These agents produce 
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sedative, hypnotic, anxiolytic, and anticonvulsant activities. They act generally by 
amplifying GABAergic transmission, such that short-acting agents have been used 
to promote sleep in insomnia patients, although more recently, effective non-
benzodiazepine hypnotics have been developed. These agents also act to facilitate 
GABAa receptor function (e.g., zolpidem and zaleplon). Insomnia is a very common 
symptom, especially in the elderly, and has a number of causes, including physical, 
social, and psychiatric. Antidepressants with sedative effects (tricyclic antide-
pressants, trazadone, nefazadone and mitrazapine) exert their effects on emotional 
state via 5-HT norepinephrine (NE) receptors, their sedative effects are seen 
through H1, 5-HT2, alpha1 receptor antagonisms. Drugs used in insomnia treat-
ment (melatonin and melatonin analogues) exert their effects via MT1 and MT2 
receptors. Other hypnotic substances acting through GABA (Valerian prepara-
tions, Gabapentin, Tiagabine), Sedative antipsychotics (Olanzapine, quetiapine; 
they are 5HT-2A antagonists), Gamma hydroxybutyrate (its mechanism of effect 
is not fully understood, it is considered to modulate dopamine activity; it is recom-
mended in narcolepsy for cataplexy treatment) [14, 15, 55, 56].
2.6.3 Antihistamines
Histaminergic projections at tuberomamillary nucleus are active during wak-
ing up. The pathology of this region leads to hypersomnia. Histaminergic inputs 
coming from TMN to RAS suppress SWS, but they do not have an effect on REM. 
RAS, basal forebrain, lateral hypothalamus and cortex have high levels of histamine 
receptors. Antihistamine (histamine receptor blockers) effects on these regions 
cause dizziness, sleepiness and cognitive dysfunction. In children first and second 
generation antihistamines can cause poisoning and coma; however, newer (third 
generation) pediatric formulations (e.g. fexofenadine, loratadine, cetirizine) seem 
to be safer [57].
2.6.4 Caffeine
The popularity of caffeine is due to its stimulant characteristics. It blocks 
adenosine receptors in RAS, decreases the inhibitor effect of adenosine; thus, 
free adenosine levels in the brain are increased resulting in a stimulant activity in 
the CNS. Caffeine appears to block adenosine A1 and A2a receptors, producing a 
psychomotor stimulant effect. Because of the high levels of A2a receptors in the 
striatum, the potential use of caffeine for the treatment of Parkinson’s disease 
has been advanced. Since adenosine A2a receptor blockade appears to protect 
dopaminergic neurons from toxic agents, a neuroprotective role has been proposed 
for caffeine in the treatment of Parkinson’s disease. Caffeine intake has also been 
associated with a decreased risk of Alzheimer’s disease, again presumably acting as 
a neuroprotective agent [12].
2.6.5 Nicotine
It is an alkaloid found in abundance in tobacco and eggplants. It is metabolized 
in the liver and its main metabolite is cotinine. With smoking low dosed of nicotine 
exerts its effects on sympathetic (tachycardia, high blood pressure) and parasym-
pathetic (tonus in the digestive system, increases in peristaltic movements and acid 
secretion) effects. (Thromboxane A2 increase, lipolysis, psychomotor stimulation, 
decreases appetite, analgesic effect, increases the secretion of ADH, ACTH, cortisol 
and insulin, decreases secretion of LH and PRL). Causes psychological and physi-
cal addiction. Inhaled nicotine in cigarette smoke is known to permeate the lungs 
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where more than 80% of the available nicotine is absorbed into the bloodstream. 
After absorption into the blood, nicotine readily crosses the blood– brain barrier 
and appears to be rapidly partitioned into brain tissue. Concentrations of nicotine 
in the brain have been reported to be 5–7 times higher than blood concentrations. 
Smokers assert that, in addition to its positive effects on concentration and atten-
tion, the primary positive effect of smoking is that it calms and relaxes. Recent 
findings suggest that one of the sites of action of nicotine may be in the RAS, 
specifically, on PPN neurons. Nicotine, at least initially, has an inhibitory effect on 
cholinergic RAS neurons, which could produce the calming effect reported upon 
inhalation of cigarette smoke. The majority of cigarettes are consumed by the men-
tally ill, especially those with disorders involving hypervigilance or hyperarousal, 
such as schizophrenia, anxiety disorders, and depression. That is, smoking may be 
a form of self-medication, presumably because of its calming effects. This effect 
(inhibition of cholinergic RAS neurons) appears to differ from the role of smoking 
in reducing the incidence of Parkinson’s disease, which appears to be manifested as 
a neuroprotective action on dopaminergic neurons by nicotine. Cerebral vasodila-
tion is seen immediately after smoking, but chronic smokers show global reductions 
in cerebral blood flow. Considering that hypofrontality is present in schizophrenia, 
anxiety disorders, and depression, the initial beneficial, calming effects of nicotine 
may be followed by deleterious consequences on cortical blood flow. Such an effect 
may drive craving for the next cigarette, creating a vicious cycle of continuous self-
administration [12, 58, 59].
2.6.6 Stimulants
The most commonly used stimulant, amphetamine, induces release of mono-
amines, especially dopamine, but also blocks their reuptake and may have neu-
rotoxic effects on nigral neurons and, more recently, is suspected of inducing the 
degenerations of certain striatal neurons. Unfortunately, this agent is abused for 
recreational purposes and continues to be prescribed for the treatment of attention 
deficit disorder (ADD). Fortunately, methylphenidate does not appear to have such 
neurotoxic effects, although its use has decreased.
Non-amphetamine stimulants: Modafinil- has been specifically produced for 
the treatment of narcolepsy. Modafinil is a newer stimulant that does not appear to 
act through dopaminergic mechanisms, like amphetamine. Modafinil does seems 
to affect structures involved in the regulation of sleep– wake states and to affect 
a number of transmitter systems, including noradrenergic, histaminergic, and 
orexinergic, as well as excitatory amino acid and serotonin release. In addition, it 
may block GABAa receptors [60–62].
2.6.7 Schizophrenia, anxiety disorder and depression
Hypofrontality, hypervigilance and sleep irregularities are common symptoms 
for these disorders. Regions in relation with RAS (cholinergic PPN, noradrenergic 
LC and serotonergic RN) that we tried to tackle so far, their neurotransmitters and 
pharmacological agents that are effective on their receptors are used for the treat-
ment of these symptoms. The serotonergic RN is known to inhibit the PPN and 
LC, with the cholinergic PPN exciting the LC and the noradrenergic LC inhibiting, 
via alpha-2 adrenergic receptors, the PPN. The PPN sends excitatory cholinergic 
projections to the substantia nigra (SN), which, in turn, sends dopaminergic pro-
jections to the striatum. The treatment of depression previously included tricyclic 
antidepressants such as amitryptiline, imipramine, and clomipramine, agents that 
mainly blocked reuptake of noradrenaline and serotonin, and blocked histamine 
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and acetylcholine release, thus accounting for increased sleepiness. The selective 
serotonin reuptake inhibitors (SSRIs) more selectively affect the RAS by increasing 
the inhibition. It is not clear if the etiology of depression is related to disinhibition 
of the PPN and LC by a decrement in serotonergic tone, although this would seem 
a likely origin for the sleep–wake symptomatology of depression. The treatment of 
anxiety disorder is involved the use of benzodiazepine amplification of GABAergic 
inhibition. In addition, the use of the alpha-2 noradrenergic receptor agonist cloni-
dine produces anxiolytic effects, probably by inhibiting autoreceptors in the LC and 
postsynaptic receptors in the PPN, thus downregulating vigilance. Because of the 
peripheral cardiovascular effects of clonidine, alpha-2 adrenergic receptor agonists 
without such actions would be more desirable. One study provided strong evidence 
for the use of the alpha-2 adrenergic receptor agonist dexmedetomidine as an 
anxiolytic for the treatment of anxiety disorders like posttraumatic stress disorder, 
panic attacks, and general anxiety disorder [32]. The etiology of anxiety disorder 
has been proposed to include downregulation or degeneration of LC outputs (pos-
sibly induced by stress hormones), which would act to release, or disinhibit, PPN 
neurons at site.
The etiology of schizophrenia has been suggested to include increased PPN 
output, accounting for marked hypervigilance and hallucinations. Excessive PPN 
output would overactivate the SN and, in turn, increase striatal release of dopamine 
that is, complying with the dopamine theory of schziophrenia. SWS are reduced in 
schizophrenics. Consistent with this assumption, lower SWA has been more often 
reported in institutionalized patients with profound cognitive impairment as well 
as in schizophrenia patients with prominent negative symptoms. The treatment of 
schizophrenia previously involved the use of the dopaminergic receptor blocker 
haloperidol, which induced tardive dyskinesia, among other serious side effects. 
Newer antipsychotics such as risperidone and quetiapine appear to block dopa-
minergic, noradrenergic, and serotonergic receptors. More striking antipsychotic 
effects were provided by the use of clozapine, which was designed as a muscarinic 
cholinergic blocker for the treatment of Parkinson’s disease [14, 63–65].
2.6.8  Motor and non-motor degenerative diseases (amyotrophic lateral sclerosis, 
Parkinson’s disease)
ALS is an incurable neurodegenerative disorder of upper and lower motor 
neurons, which is characterized by degeneration of the corticospinal tracts, result-
ing in loss of motor neurons in the brain, brainstem and anterior horn cells of the 
spinal cord. Loss of motor neurons in the brainstem and spinal cord causes weakness 
of the pharyngeal, laryngeal, intercostal and diaphragmatic muscles. During non-
REM sleep, muscle tone is decreased and during REM sleep muscle tone is almost 
completely lost. Automatic ventilation during sleep is almost completely dependent 
on the diaphragm (particularly in REM sleep) therefore diaphragmatic dysfunction 
(such as that seen in ALS) can predispose to hypoventilation and nocturnal hypox-
emia. Parkinson Disease [PD] is the second most common neurodegenerative disor-
der after Alzheimer’s disease. PD occurs as a result of chronic, progressive decrease in 
dopamine levels of the substantia nigra, secondary to loss of dopaminergic neurons in 
the pars compacta and the occurrence of Lewy bodies in the cytoplasm of remaining 
neurons. It is primarily diagnosed clinically and patients may present with the char-
acteristic motor deficits, which include the resting tremor, bradykinesia, rigidity and 
postural instability. However, most will have both motor and nonmotor symptoms. 
The nonmotor symptoms cause disturbances, which affect sleep, mood, cognition, 
sensation and autonomic function. Among the nonmotor symptoms in PD, sleep 
disorders are second in frequency only to neuropsychiatric disorder [16, 65–68].
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2.6.9  Analytical functions of molecules affecting sleep in neurophysiology and 
physiopathology
Particular attention to hormonal conditions is warranted. After all, the first sign 
of puberty is pulsatile hormone (LH) release during sleep. For example, narcolepsy 
is tightly linked with certain human leukocyte antigen (HLA) haplotypes, suggest-
ing that it is an autoimmune disorder. Kleine– Levin syndrome, discussed earlier, is 
linked to similar haplotypes, which suggests an autoimmune etiology. Interestingly, 
in most cases of narcolepsy, Kleine– Levin syndrome, as well as schizophrenia, 
panic attacks, obsessive– compulsive disorder, and other disorders, the age of onset 
is soon after puberty. Along other lines, in about 20% of schizophrenic patients, 
the mother had an influenza attack during the second trimester, while narcoleptics 
are born predominantly during the late winter– early spring, that is, after influenza 
season. It has been suggested that developmental dysregulation, either pre- or 
perinatally (initial insult), becomes pathologically manifest after exposure to 
puberty and its hormonal onslaught. These considerations point to complex interac-
tions between development, environment, and hormonal status, all of which seem 
to affect sleep– wake regulation in as yet unknown ways. These findings suggest 
that the effects of hormones, either prescribed or taken as dietary supplements, or 
abused, need to be more closely studied and considered in the design of therapeutic 
interventions [69, 70].
Brain energy requirements are extraordinarily high; any modification in glucose 
utilization by the brain may profoundly affect glucose tolerance. Cerebral glucose 
utilization is lower during SWS than during either REM sleep or wake. Using PET 
scans, a strong correlation was evidenced between slow-wave activity, an index of 
the intensity of SWS, and regional blood flow in the prefrontal brain. Furthermore, 
experimental studies, involving continuous enteral nutrition or intravenous glucose 
infusion while allowing for normal nocturnal sleep, have shown that glucose 
tolerance is minimal during the first half of the sleep period, i.e. when SWS is the 
dominant sleep stage. These findings confirm the existence of a robust link between 
SWS and glucose tolerance. Both reduction in total sleep duration with slow-wave 
sleep (SWS) largely preserved and alterations of sleep quality (especially marked 
reduction of SWS) with preservation of total sleep duration areassociated with 
insulin resistance without compensatory increase in insulin secretion, resulting in 
impaired glucose tolerance and increased risk of type 2 diabetes. When performed 
under rigorously controlled conditions of energy intake and physical activity, 
sleep restriction is also associated with a decrease in circulating levels of leptin 
(an anorexigenic hormone) and an increase in circulating levels of ghrelin (an 
orexigenic hormone), hunger and appetite. Furthermore, sleep restriction is also 
associated with a stimulation of brain regions sensitive to food stimuli, indicating 
that sleep loss may lead to obesity through the selection of high-calorie food. There 
is also evidence that sleep restriction could provide a permissive environment for 
the activation of genes that promote obesity. Indeed, the heritability of body mass 
index is increased in short sleepers. Thus, chronic sleep curtailment, which is on the 
rise in modern society, including in children, is likely to contribute to the current 
epidemics of type 2 diabetes and obesity [71–73].
Chronic sleep loss is increasingly common in industrialized societies, affecting 
about 45% of adults. Sleep deprivation induces behavioral, hormonal, and neuro-
chemical alterations. The stress inherent in sleep deprivation causes changes in the 
concentration of hormones such as cortisol as well as in prolactin and estradiol, 
which are known to influence dopaminergic transmission.
Studies have suggested that dopamine (DA) is responsible for the behavioral 
changes observed after sleep deprivation. Specifically, REM sleep deprivation has 
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been shown to be related to changes in D2 post-synaptic receptor sensitivity in the 
rat striatum. DA transporter (DAT) knockout mice exhibit increased wakefulness 
and less SWS. REM sleep would induce increases in dopaminergic activity after 
sleep deprivation and selective REM sleep deprivation for a prolonged period would 
result in down-regulation of DAT, enhancing dopaminergic neurotransmission. 
Amphetamine derivatives inhibit DAT-mediated DA reuptake [74, 75].
Short-term sleep deprivation has shown therapeutic properties for with mood 
disorders, long-term/ chronic sleep deprivation and disruption have instead been 
related to the development of mood disorders via monoamine (5-HT, NE, DA) 
activity dysregulation. The main symptoms of depression are due to a functional 
deficiency of the brain monoaminergic transmitters: norepinephrine, serotonin 
and/or dopamine, whereas mania is caused by a functional excess of monoamines 
at critical synapses in the brain. Although recently some observations have chal-
lenged the legitimacy of this theory, a dysregulation in monoamine production 
and transmission is still considered an important factor in the regulation of mood, 
emotions, cognition, motivational behaviors and stress responses. Deuschle et al. 
[81] conducted a study in a group of individuals suffering from chronic insomnia, 
and found that the short allele of the 5-HT transporter was significantly more 
frequent in patients suffering from insomnia than in good sleepers. Roman et al. 
[82] suggested that chronic sleep restriction may increase an individual’s vulnerabil-
ity to develop mood disorders by impairing serotoninergic transmission throughout 
the activation of the stress system The genetic makeup of the dopamine system 
involved in vulnerability to mood disorders has also been shown to be involved 
in the response to sleep loss and in alterations in responses to reward in humans. 
A polymorphism in the dopamine 2 receptor, more commonly in the dopamine 
transporter system, has been related to a vulnerability to psychiatric disorders in the 
presence of sleep deprivation in humans. It has been widely shown that individuals 
suffering from insomnia display hyperactivation of the hypothalamic–pituitary– 
adrenal-axis at both brain and peripheral levels. Increases in norepinephrine, 
epinephrine and other markers of sympathetic outflow have been related to 
cognitive and emotional arousal and somatic hyperarousal in individuals suffering 
from insomnia: it is the key pathophysiological mechanism of insomnia. Changes 
observed in brain structures in individuals suffering from insomnia include a 
reduction in the volume of the prefrontal cortex, caudate head and hippocampus, 
as well as an increase in the amygdala volume, modifications resembling those 
described in individuals suffering mood disorders. Given these similarities, it has 
been hypothesized that insomnia may influence the development and maintenance 
of a mood disorder throughout the activation of the stress system and of its negative 
consequences on the brain, including hippocampal neurogenesis, synaptic plasticity 
and connectivity [76–85].
Finally, we can talk about the relationship between sleep and antidepressants, which 
are effective on monoamine (5-HT, NE, DA) activity systems in the brain: (1) Tricyclic 
antidepressants (TCA) (antagonist of 5HT-1, NE, M1, H1 receptors); (a) tertiary TCAs 
shorten sleep latency and reduce awakenings during sleep. Therefore, it is perceived as 
a sedative; doxepin and amitriptyline decrease REM rate in sleep EEG, cause prolonga-
tion of REM sleep latency, (b) Secondary TCAs such as desipramine are less sedative 
and relatively stimulating, (c) potent serotoninergic TCAs such as clomipramine 
increase eye movements in NREM. It increases the periodic leg movements during 
sleep, (2) nonspecific reuptake inhibitors (5HT, NE DA); trazadone is sedative and 
nefazodone is less sedative, they increase SWS sleep, (3) monoamine oxidase inhibi-
tors (MAOI) (eg, tranylcypromine, moclobemide), (4) selective serotonin reuptake 
inhibitors SSRI (eg, fluoxetine, escitalopram, paroxetine, sertraline), (5) serotonin and 
norepinephrine reuptake inhibitors (SNRI) (eg, venlafaxine, duloxetine, reboxetine) 
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(6) Bupropion (inhibition of norepinephrine and dopamine reuptake) these agents 
increase SWS, prolong REM latency, shorten REM time, (7) Agomelatine (agonism at 
melatonin M1 and M2 receptors, antagonism at serotonergic 5-HT2C receptors) have 
been found to increase SWS [86–89].
2.6.10 Conclusion
The more we learn about the neurophysiology of sleep and the effects of related 
molecules, the better we understand the pathological processes in wakefulness. 
Understanding the functioning of the sleep brain, along with neurotransmitters, 
hormones, and new molecules, will explain unknown physiological processes and 
inspire innovative processes in pharmacology.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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